169 related articles for article (PubMed ID: 16810308)
1. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease.
Fukagawa M; Nakanishi S; Kazama JJ
Kidney Int Suppl; 2006 Jul; (102):S3-7. PubMed ID: 16810308
[TBL] [Abstract][Full Text] [Related]
2. [Significance of point of no return in therapeutic strategy for treatment of renal osteodystrophy; from histopathological findings].
Koiwa F; Hirose M
Clin Calcium; 2004 Sep; 14(9):46-52. PubMed ID: 15577109
[TBL] [Abstract][Full Text] [Related]
3. [Cell proliferation of parathyroid gland in patients with progressive secondary hyperparathyroidism: Vitamin D receptor, calcium sensing receptor, and cell cycle regulation factor].
Tokumoto M; Taniguchi M; Matsuo D; Tsuruya K; Hirakata H; Iida M
Clin Calcium; 2005 Sep; 15 Suppl 1():206-16. PubMed ID: 16279026
[No Abstract] [Full Text] [Related]
4. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
[TBL] [Abstract][Full Text] [Related]
5. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis.
Taniguchi M; Tokumoto M; Matsuo D; Motoyama K; Sugitani A; Kuroki S; Yotsueda H; Tsuruya K; Hirakata H; Iida M
Kidney Int; 2006 Jul; 70(2):363-70. PubMed ID: 16738533
[TBL] [Abstract][Full Text] [Related]
6. Regulation of parathyroid function in chronic kidney disease (CKD).
Fukagawa M; Nakanishi S; Fujii H; Hamada Y; Abe T
Clin Exp Nephrol; 2006 Sep; 10(3):175-9. PubMed ID: 17009074
[TBL] [Abstract][Full Text] [Related]
7. NF-κB activation contributes to parathyroid cell proliferation in chronic kidney disease.
Kan S; Zhang W; Mao J; Wang M; Ni L; Zhang M; Zhang Q; Chen J
J Nephrol; 2018 Dec; 31(6):941-951. PubMed ID: 30171599
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and medical treatment of secondary hyperparathyroidism.
Fukagawa M; Kurokawa K
Semin Surg Oncol; 1997; 13(2):73-7. PubMed ID: 9088062
[TBL] [Abstract][Full Text] [Related]
9. Direct injection of calcitriol or its analog into hyperplastic parathyroid glands induces apoptosis of parathyroid cells.
Shiizaki K; Negi S; Hatamura I; Tatsuta K; Shibata M; Shimada S; Sakaguchi T; Akizawa T
Kidney Int Suppl; 2006 Jul; (102):S12-5. PubMed ID: 16810304
[TBL] [Abstract][Full Text] [Related]
10. Calcium-sensing receptor and apoptosis in parathyroid hyperplasia of patients with secondary hyperparathyroidism.
Lee HJ; Seo UH; Kim WY; Woo SU; Lee JB
J Int Med Res; 2013 Feb; 41(1):97-105. PubMed ID: 23569134
[TBL] [Abstract][Full Text] [Related]
11. The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.
Arcidiacono MV; Yang J; Fernandez E; Dusso A
Nephrol Dial Transplant; 2015 Mar; 30(3):423-33. PubMed ID: 25294851
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
Am J Nephrol; 2013; 37(5):405-12. PubMed ID: 23594726
[TBL] [Abstract][Full Text] [Related]
13. Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach.
Fukagawa M; Kitaoka M; Kurokawa K
Nephrol Dial Transplant; 1996; 11 Suppl 3():125-9. PubMed ID: 8840327
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27.
Tokumoto M; Tsuruya K; Fukuda K; Kanai H; Kuroki S; Hirakata H; Iida M
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii9-12. PubMed ID: 12771291
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy.
Tominaga Y; Matsuoka S; Sato T; Uno N; Goto N; Katayama A; Haba T;
Ther Apher Dial; 2007 Aug; 11(4):266-73. PubMed ID: 17661832
[TBL] [Abstract][Full Text] [Related]
16. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
Cunningham J; Locatelli F; Rodriguez M
Clin J Am Soc Nephrol; 2011 Apr; 6(4):913-21. PubMed ID: 21454719
[TBL] [Abstract][Full Text] [Related]
17. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism.
Tominaga Y; Tanaka Y; Sato K; Nagasaka T; Takagi H
Semin Surg Oncol; 1997; 13(2):78-86. PubMed ID: 9088063
[TBL] [Abstract][Full Text] [Related]
18. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism.
Tokumoto M; Tsuruya K; Fukuda K; Kanai H; Kuroki S; Hirakata H
Kidney Int; 2002 Oct; 62(4):1196-207. PubMed ID: 12234290
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid Nodular Hyperplasia and Responsiveness to Drug Therapy in Renal Secondary Hyperparathyroidism: An Open Question.
Vulpio C; Bossola M
Ther Apher Dial; 2018 Feb; 22(1):11-21. PubMed ID: 28980761
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice.
Arcidiacono MV; Yang J; Fernandez E; Dusso A
Nephrol Dial Transplant; 2015 Mar; 30(3):434-40. PubMed ID: 25324357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
